RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Abcellera Biologics Stock

Abcellera Biologics P/E 2024

Abcellera Biologics P/E

-6.18

Ticker

ABCL

ISIN

CA00288U1066

WKN

A2QKXS

As of Sep 21, 2024, Abcellera Biologics's P/E ratio was -6.18, a -53.91% change from the -13.41 P/E ratio recorded in the previous year.

The Abcellera Biologics P/E history

Abcellera Biologics Aktienanalyse

What does Abcellera Biologics do?

Abcellera Biologics Inc. is a leading biotechnology company specializing in the discovery of antibodies and the identification of therapies for serious diseases. The company was founded in Vancouver, Canada in 2012 and has since become a major player in the biotechnology field. It has formed numerous significant partnerships with large pharmaceutical companies in recent years and works closely with leading universities and research institutions worldwide. Abcellera Biologics Inc. follows a new, innovative business model that focuses on the discovery of antibodies through the application of cutting-edge technologies, data science, and machine learning. The company has developed a revolutionary technology platform called "Microfluidic Drop-based Technology" that is capable of discovering thousands of antibodies within just a few weeks. This technology allows for the rapid and efficient discovery of antibodies that can be used in the treatment of serious diseases. Abcellera Biologics Inc. is divided into several divisions that focus on antibody discovery, therapy development, collaborations with pharmaceutical companies, and services. Antibody discovery is carried out through years of research and development using state-of-the-art technologies and methods. Therapy development includes preclinical and clinical development of therapeutic products and conducting clinical trials. Abcellera Biologics Inc. works closely with leading pharmaceutical companies in the industry to develop new therapies and discover antibodies. The company has already formed numerous partnerships with major pharmaceutical companies such as Pfizer, Sanofi, GlaxoSmithKline, AbbVie, and Biogen. Another important focus of Abcellera Biologics Inc. is providing services in the field of antibody development. The company has extensive expertise in antibody discovery and therefore offers services to other companies. This allows other companies to benefit from Abcellera Biologics Inc.'s unique technology platform and top-notch capabilities. Abcellera Biologics Inc.'s product portfolio includes various antibody therapies targeting the treatment of specific diseases. One of the company's most promising products is the "LY-CoV555" antibody therapy used for COVID-19. This therapy was developed in collaboration with Eli Lilly and is currently being tested in clinical trials. Overall, Abcellera Biologics Inc. has become a leading company in the biotechnology industry. Its focus on antibody discovery through state-of-the-art technologies and data-driven methods, as well as successful collaborations with major pharmaceutical companies, makes it an important player in the industry. Abcellera Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Abcellera Biologics's P/E Ratio

The Price to Earnings (P/E) Ratio of Abcellera Biologics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Abcellera Biologics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Abcellera Biologics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Abcellera Biologics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Abcellera Biologics stock

What is the price-to-earnings ratio of Abcellera Biologics?

The price-earnings ratio of Abcellera Biologics is currently -6.18.

How has the price-earnings ratio of Abcellera Biologics changed compared to last year?

The price-to-earnings ratio of Abcellera Biologics has increased by -53.91% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Abcellera Biologics high compared to other companies?

Yes, the price-to-earnings ratio of Abcellera Biologics is high compared to other companies.

How does an increase in the price-earnings ratio of Abcellera Biologics affect the company?

An increase in the price-earnings ratio of Abcellera Biologics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Abcellera Biologics affect the company?

A decrease in the price-earnings ratio of Abcellera Biologics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Abcellera Biologics?

Some factors that influence the price-earnings ratio of Abcellera Biologics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Abcellera Biologics pay?

Over the past 12 months, Abcellera Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abcellera Biologics is expected to pay a dividend of 0 USD.

What is the dividend yield of Abcellera Biologics?

The current dividend yield of Abcellera Biologics is .

When does Abcellera Biologics pay dividends?

Abcellera Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Abcellera Biologics?

Abcellera Biologics paid dividends every year for the past 0 years.

What is the dividend of Abcellera Biologics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Abcellera Biologics located?

Abcellera Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Abcellera Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Abcellera Biologics from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Abcellera Biologics pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Abcellera Biologics in the year 2023?

In the year 2023, Abcellera Biologics distributed 0 USD as dividends.

In which currency does Abcellera Biologics pay out the dividend?

The dividends of Abcellera Biologics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Abcellera Biologics

Our stock analysis for Abcellera Biologics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abcellera Biologics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.